ArticleArchives of insect biochemistry and physiology2026
Cytotoxic and Immunological Effects of Terpinolene and 1-butyl-3,4-methylenedioxybenzene on Aedes aegypti Larvae.
Article in Archives of insect biochemistry and physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Interactions between biomolecules and their target sites are fundamental to pest control, and such relationships can either intensify or inhibit their effects. A broader understanding of these complex interactions aids in interpreting toxicological responses, while physiological changes can elucidate insect metabolic pathways. Research involving terpinolene and 1-butyl-3,4-methylenedioxybenzene (BMDB) has demonstrated their insecticidal activity against Aedes aegypti. However, the effects of these substances on physiological and immunological parameters require further clarification; furthermore, the binary combination of these compounds may result in more significant and permanent damage. Thus, this study aimed to test the hypothesis that combining different modes of action would intensify histological and immunological alterations critical to insect survival, thereby enabling more effective control. To this end, LC50 values for the individual compounds were obtained from the literature (Silva et al. 2016), and a dose-response curve was established for the 1:1 combination, revealing an LC50 of 75.69 ± 2.37 ppm. The cytotoxic parameters evaluated included midgut histology, apoptosis, and cell proliferation in L4-stage larvae, while immunological parameters evaluated included phenoloxidase activity, nitric oxide levels, and oxidative stress markers (TBARS and GST). Histological changes in the midgut were observed in all treatment groups compared to the control; however, more severe histopathological alterations-such as vacuolization, cellular swelling, and loss of the peritrophic matrix-were observed in the combined treatment. Regarding apoptosis, a significant increase was observed only in treatments containing BMDB, whether alone (2.66 ± 0.66) or in combination (3.33 ± 0.33), compared to the control (0.5 ± 0.54). As for cell proliferation (PCNA), larvae in the combined group exhibited a lower rate (0.50 ± 0.11) compared to terpinolene (1.33 ± 0.12) and BMDB (1.40 ± 0.15). Reductions in phenoloxidase activity (1.026 ± 0.061 OD/min/mg) and nitric oxide levels (0.878 ± 0.034 µM/mL) were observed in the combined group. Regarding oxidative stress, there was no statistical difference in GST measurements (p > 0.05), whereas TBARS levels decreased in the combined group (2.497 ± 0.184 nmol MDA/mg/protein) compared to the control (3.401 ± 0.327 nmol MDA/mg/protein). Thus, despite exhibiting lower larvicidal activity compared to the isolated compounds, the binary combination caused more severe histopathological and immunological damage that compromises larval survival and recovery capacity, representing a promising strategy for integrated vector management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.